Aquestive Therapeutics to Host Virtual Investor Day on September 27 to Provide Pipeline Updates Page 1

WARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company developing medicines to meaningfully improve patients’ lives through innovative science and delivery technologies, today announced that it will host a virtual investor day on September 27, 2024 at 8:00 a.m. ET to discuss the Company’s pipeline updates, including Anaphylm (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel, both product candidates derived from the Company’s Adrenaverse epinephrine prodrug platform. The event will include presentations by members of Aquestive’s management team as well as key opinion leader J. David Farrar, PhD, Associate Professor, Immunology/Molecular Biology, UT Southwestern Medical Center.

To attend the event, please register here. Following the event, the Adrenaverse Investor Day webcast and accompanying presentation will be accessible via the Events & Presentations page in the Investors section of the Company’s website at https://investors.aquestive.com/events-and-presentations. The webcast will be archived for 30 days.

About Anaphylm
Anaphylm (epinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a pocket, and is designed to withstand weather conditions such as exposure to rain and/or sunlight. The Anaphylm trade name for AQST-109 has been conditionally approved by the FDA. Final approval of the Anaphylm brand name is contingent upon FDA approval of the product candidate.

About AQST-108
AQST-108 (epinephrine) Topical Gel is an epinephrine prodrug topical gel product candidate. Aquestive completed a first in human study for AQST-108 that measured the amount of epinephrine retained on the skin or detected in the bloodstream following application of the gel. AQST-108 is based on Aquestive’s Adrenaverse platform, which contains a library of over twenty epinephrine prodrug product candidates designed to control absorption and conversion rates across a variety of potential dosage forms and administration sites.

Diskutieren Sie über die entaltenen Werte